Vita Actives has entered into a partnership with Brudy Technology to utilise its Tridocosahexaenoína-AOX DHA molecule.
Through this collaboration, Vita Actives will launch UbiOmega, a concentrated DHA nutraceutical sourced from both fish and algae.
This will allow global dietary supplement brands to access a bioavailable omega-3 option that is backed by more than 20 years of research.
According to Brudy, its Tridocosahexaenoína-AOX DHA ingredient has been clinically demonstrated to support:
- Eye health
- Maternal and infant health
- Active nutrition
Tridocosahexaenoína-AOX has been commercially available through BrudyLab's range of own-brand dietary supplements since 2010, and has been optimised to ensure superior bioavailability, antioxidant capacity and anti-inflammatory benefits.
CEO of Vita Actives, Deepak Sharma, commented: “We are thrilled to partner with Brudy Technology. Their expertise in DHA innovation aligns perfectly with our commitment to delivering cutting-edge, research-backed ingredients to brands in the health and wellness sectors.”
“The Tridocosahexaenoína-AOX DHA molecule stands out as one of the most clinically researched omega-3 solutions available, with an exceptional ability to support eye health, brain health and sports applications. This partnership marks a significant step forward in our mission to bring cutting-edge, scientifically validated ingredients to the market.”.
Brudy Technology's CEO, Dr Francisco Gasso Casademunt, added: “Our Tridocosahexaenoína-AOX molecule has been the cornerstone of our success, helping millions of consumers through products that support eye health, fertility, maternal health and overall well-being."
"In partnering with Vita Actives, we are excited to bring our technology to a broader audience in the dietary supplement industry. Their global reach and shared commitment to innovation make them the ideal partner for us.”